Jim Simons Autolus Therapeutics PLC Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q2 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,751,200 shares of AUTL stock, worth $3.77 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,751,200

Previous 1,584,125 10.55%

Holding current value

$3.77 Million

Previous $2.46 Million 62.61%

% of portfolio

0.01%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$1.14 - $2.4 $190,465 - $400,980	167,075 Added 10.55%	1,751,200 $3.99 Million
Q1 2025 May 14, 2025	BUY	$1.55 - $2.68 $1.5 Million - $2.59 Million	965,183 Added 155.94%	1,584,125 $2.46 Million
Q4 2024 Feb 13, 2025	BUY	$2.18 - $4.8 $802,394 - $1.77 Million	368,071 Added 146.72%	618,942 $1.45 Million
Q3 2024 Nov 13, 2024	SELL	$3.38 - $4.69 $3.02 Million - $4.19 Million	-894,185 Reduced 78.09%	250,871 $910,000
Q2 2024 Aug 09, 2024	BUY	$3.33 - $5.68 $2.73 Million - $4.66 Million	821,156 Added 253.52%	1,145,056 $3.98 Million
Q1 2024 May 13, 2024	BUY	$5.39 - $7.29 $885,577 - $1.2 Million	164,300 Added 102.94%	323,900 $2.07 Million
Q4 2023 Feb 13, 2024	SELL	$2.13 - $6.63 $242,988 - $756,343	-114,079 Reduced 41.68%	159,600 $1.03 Million
Q3 2023 Nov 14, 2023	BUY	$2.32 - $3.36 $284,151 - $411,529	122,479 Added 81.0%	273,679 $638,000
Q2 2023 Aug 11, 2023	BUY	$1.64 - $3.21 $70,192 - $137,388	42,800 Added 39.48%	151,200 $360,000
Q1 2023 May 12, 2023	BUY	$1.75 - $2.25 $108,675 - $139,725	62,100 Added 134.13%	108,400 $199,000
Q4 2022 Feb 13, 2023	BUY	$1.74 - $3.27 $36,714 - $68,997	21,100 Added 83.73%	46,300 $88,000
Q3 2022 Nov 14, 2022	BUY	$2.04 - $3.76 $25,296 - $46,624	12,400 Added 96.88%	25,200 $54,000
Q2 2022 Aug 12, 2022	BUY	$2.04 - $4.68 $26,112 - $59,904	12,800 New	12,800 $36,000
Q2 2021 Aug 13, 2021	SELL	$4.78 - $7.96 $389,990 - $649,440	-81,588 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$5.49 - $9.36 $3,469 - $5,915	632 Added 0.78%	81,588 $467,000
Q4 2020 Feb 10, 2021	BUY	$8.13 - $12.79 $221,949 - $349,167	27,300 Added 50.88%	80,956 $724,000
Q3 2020 Nov 13, 2020	SELL	$11.64 - $16.3 $218,180 - $305,527	-18,744 Reduced 25.89%	53,656 $625,000
Q2 2020 Aug 13, 2020	SELL	$5.38 - $16.14 $473,956 - $1.42 Million	-88,096 Reduced 54.89%	72,400 $1.16 Million
Q1 2020 May 14, 2020	BUY	$4.2 - $13.0 $503,143 - $1.56 Million	119,796 Added 294.34%	160,496 $961,000
Q4 2019 Feb 13, 2020	SELL	$11.13 - $16.28 $92,379 - $135,124	-8,300 Reduced 16.94%	40,700 $537,000
Q3 2019 Nov 13, 2019	SELL	$9.79 - $16.72 $402,329 - $687,125	-41,096 Reduced 45.61%	49,000 $609,000
Q2 2019 Aug 12, 2019	BUY	$15.1 - $31.25 $1.36 Million - $2.82 Million	90,096 New	90,096 $1.45 Million

Others Institutions Holding AUTL

# of Institutions

100

Shares Held

165M

Call Options Held

Put Options Held

39.3K

View Full List

About Autolus Therapeutics plc

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $195M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

More about AUTL

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account